Janssen Alzheimer’s Patent Not Valid: Fed. Circ.

Law360, New York (September 25, 2009, 7:05 PM EDT) -- A federal appeals court has upheld a decision that invalidated Janssen Pharmaceutica NV’s patent covering a method for treating Alzheimer’s disease, handing a victory to a group of generic-drug companies accused of infringing the patent.

In a 2-1 decision, the U.S. Court of Appeals for the Federal Circuit on Friday affirmed a district court’s ruling that Janssen’s patent was invalid because of lack of enablement, finding that the patent application did not establish utility.

The patent, issued in 1987 and licensed to Janssen in 1995, covers...
To view the full article, register now.